Chi Him Kendrick Yiu

Chi Him Kendrick Yiu

Auto-generated profile, based on publicly available information

Chi Him Kendrick Yiu

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
MAMarisa Assunção
Marisa Assunção
CYChi Him Kendrick Yiu
Chi Him Kendrick Yiu
HWHo-Ying Wan
Ho-Ying Wan
MWMichelle Dan Wan
Michelle Dan Wan
DKDai Fei Elmer Ker
Dai Fei Elmer Ker
Ana BlockiAna Blocki
Ana Blocki
Hyaluronic acid (HA)-based biomaterials have been demonstrated to promote wound healing and tissue regeneration, owing to the intrinsic and important role of HA in these processes. A deeper understanding of the biological functions of HA would enable better informed decisions on applications involving HA-based biomaterial design. HA and fibronectin are both major components of the provisional extracellular matrix (ECM) during wound healing and regeneration. Both biomacromolecules exhibit the same spatiotemporal distribution, with fibronectin possessing direct binding sites for HA. As HA is one of the first components present in the wound healing bed, we hypothesized that HA may be involved in the deposition, and subsequently fibrillogenesis, of fibronectin. This hypothesis was tested by exposing cultures of mesenchymal stromal cells (MSCs), which are thought to be involved in the early phase of wound healing, to high molecular weight HA (HMWHA). The results showed that treatment of human bone marrow derived MSCs (bmMSCs) with exogenous HMWHA increased fibronectin fibril formation during early ECM deposition. On the other hand, partial depletion of endogenous HA led to a drastic impairment of fibronectin fibril formation, despite detectable granular presence of fibronectin in the perinuclear region, comparable to observations made under the well-established ROCK inhibition-mediated impairment of fibronectin fibrillogenesis. These findings suggest the functional involvement of HA in effective fibronectin fibrillogenesis. The hypothesis was further supported by the co-alignment of fibronectin, HA and integrin α5 at sites of ongoing fibronectin fibrillogenesis, suggesting that HA might be directly involved in fibrillar adhesions. Given the essential function of fibronectin in ECM assembly and maturation, HA may play a major enabling role in initiating and propagating ECM deposition. Thus, HA, as a readily available biomaterial, presents practical advantages for de novo ECM-rich tissue formation in tissue engineering and regenerative medicine.

25 March 2025 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
FLFrancis J. A. Leblanc
Francis J. A. Leblanc
CYChi Him Kendrick Yiu
Chi Him Kendrick Yiu
LMLucia M. Moreira
Lucia M. Moreira
AJAaron M. Johnston
Aaron M. Johnston
NMNeelam Mehta
Neelam Mehta
GLGuillaume Lettre
Guillaume Lettre
The dysregulation of gene expression programs in the human atria during persistent atrial fibrillation (AF) is not completely understood. Here, we reanalyze bulk RNA-sequencing datasets from two studies (N = 242) and identified 755 differentially expressed genes in left atrial appendages of individuals with persistent AF and non-AF controls. We combined the bulk RNA-sequencing differentially expressed genes with a left atrial appendage single-nucleus multi-omics dataset to assign genes to specific atrial cell types. We found noncoding genes at the IFNG locus (LINC01479, IFNG-AS1) strongly dysregulated in cardiomyocytes. We defined a gene expression signature potentially driven by androgen receptor signaling in cardiomyocytes from individuals with AF. Cell-type-specific gene expression modules suggested an increase in T cell and a decrease in adipocyte and neuronal cell gene expression in AF. Lastly, we showed that reducing NR4A1 expression, a marker of a poorly characterized human atrial fibroblast subtype, fibroblast activation markers, extracellular matrix remodeling and cell proliferation decreased.

1 November 2022 in Bioactive Materials
Verified
Journal Article
Open access
TSThomas Später
Thomas Später
MAMarisa Assunção
Marisa Assunção
KLKwok Keung Lit
Kwok Keung Lit
GGGuidong Gong
Guidong Gong
XWXiaoling Wang
Xiaoling Wang
Ana BlockiAna Blocki
Ana Blocki
Tissue (re)vascularization strategies face various challenges, as therapeutic cells do not survive long enough in situ, while the administration of pro-angiogenic factors is hampered by fast clearance and insufficient ability to emulate complex spatiotemporal signaling. Here, we propose to address these limitations by engineering a functional biomaterial capable of capturing and concentrating the pro-angiogenic activities of mesenchymal stem cells (MSCs). In particular, dextran sulfate, a high molecular weight sulfated glucose polymer, supplemented to MSC cultures, interacts with MSC-derived extracellular matrix (ECM) components and facilitates their co-assembly and accumulation in the pericellular space. Upon decellularization, the resulting dextran sulfate-ECM hybrid material can be processed into MIcroparticles of SOlidified Secretome (MIPSOS). The insoluble format of MIPSOS protects protein components from degradation, while facilitating their sustained release. Proteomic analysis demonstrates that MIPSOS are highly enriched in pro-angiogenic factors, resulting in an enhanced pro-angiogenic bioactivity when compared to naïve MSC-derived ECM (cECM). Consequently, intravital microscopy of full-thickness skin wounds treated with MIPSOS demonstrates accelerated revascularization and healing, far superior to the therapeutic potential of cECM. Hence, the microparticle-based solidified stem cell secretome provides a promising platform to address major limitations of current therapeutic angiogenesis approaches.

24 April 2026 in Circulation Research
Verified
Journal Article
Open access
RTRoman Tikhomirov
Roman Tikhomirov
VBVeronika Boichenko
Veronika Boichenko
BRBenedict Reilly-O'Donnell
Benedict Reilly-O'Donnell
CLCarla Lucarelli
Carla Lucarelli
PSPrashant Kumar Srivastava
Prashant Kumar Srivastava
JGJulia Gorelik
Julia Gorelik
BACKGROUND: Cardiac fibrosis can be triggered by several pathologies, including ischemic heart disease and aortic stenosis. Cardiac fibrosis is brought about by uncontrolled ECM (extracellular matrix) deposition by myofibroblasts. IL (interleukin)-11 ( Il11 ) has been demonstrated as a trigger of multiorgan fibrosis. However, the molecular mechanisms underpinning IL-11–induced fibrosis require further characterization. Recent studies indicate that microRNA dysregulation contributes to the pathogenesis of cardiac fibrosis and can be targeted therapeutically. This study explored the hypothesis that microRNAs act as downstream effectors of IL-11–induced cardiac fibrosis. Moreover, we investigated the translational potential of IL-11–regulated microRNAs as circulating biomarkers of cardiac fibrosis in patients with aortic stenosis. METHODS: A bioinformatic microRNA target prediction analysis was used to identify candidate microRNAs regulated by IL-11. Experimental validation was performed in cardiac fibroblasts from postinfarction failing and healthy rat hearts, after IL-11 stimulation. Functional studies assessed the effects of microRNA modulation on fibrotic gene expression in cardiac fibroblasts using microRNA inhibitor–based and mimic-based transfection. Bioinformatic analysis and luciferase assay identified candidate microRNA targets downstream of IL-11. Findings were further evaluated in transverse aortic constriction and cardiomyocyte-specific Il11 -overexpression (Tg-Il11 [transgenic mouse model with cardiomyocyte-specific Il11 overexpression]) mouse models and in left ventricular tissue, peripheral plasma, and plasma extracellular vesicles from patients with aortic stenosis. RESULTS: MicroRNA-27b-5p and microRNA-497-5p were identified as novel downstream effectors of IL-11 signaling. IL-11 increased the expression of both microRNAs in cardiac fibroblasts; transfection with either microRNA inhibitor reduced, whereas microRNA mimics increased, profibrotic mRNA levels. Furthermore, microRNA-27b-5p and microRNA-497-5p converged on HIF (hypoxia-inducible factor)-1 signaling by targeting its regulator EGLN (Egl-9 family hypoxia-inducible factor). Increased microRNA levels were observed alongside reduced expression of Egln1 and Egln2 in 2 mouse models. In patients with aortic stenosis, myocardial and circulating levels of these microRNAs correlated with the severity of left ventricular fibrosis, indicating these microRNAs’ potential as new circulating biomarkers of cardiac fibrosis. CONCLUSIONS: In this study, we have newly identified the potential value of microRNA-27b-5p and microRNA-497-5p as actionable biomarkers of the profibrotic response to IL-11 in the heart. Future studies should validate the translational potential of the microRNAs as new clinical biomarkers and therapeutic targets.

7 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
JTJasha Trompf
Jasha Trompf
KCKathryn Cox
Kathryn Cox
MHMohit Hulsurkar
Mohit Hulsurkar
LMLucia M. Moreira
Lucia M. Moreira
CYChi Him Kendrick Yiu
Chi Him Kendrick Yiu
SRSvetlana Reilly
Svetlana Reilly
Atrial fibrillation (AF), the commonest cardiac arrhythmia, is a major contributor to mortality and morbidity. Atrial tissue fibrosis, a hallmark of structural remodelling in AF, is currently incurable and significantly hinders AF-treatment. MicroRNA(miR)-31 is linked to ageing (a key risk factor for AF). Here, we show that AF-patients are characterised by upregulation of miR-31-5p in atrial cardiofibroblasts that negatively regulates the calcitonin receptor (CTR), thereby promoting atrial fibrogenesis and arrhythmia. Specific blockade of miR-31-5p/CTR-mRNA binding with LNA-miRNA-Target-Site-Blocker selectively increases atrial CTR expression and reverses advanced atrial fibrosis and arrhythmogenesis in vivo. These findings suggest a key role for miR-31-5p/CTR binding in promoting atrial fibrosis and arrhythmogenesis, and represents a first example of an RNA-based therapeutic capable of reversing established fibrosis that forms an AF substrate. *Jasha Trompf, Kathryn Cox, and Mohit Hulsurkar contributed equally to this work.

1 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CYChi Him Kendrick Yiu
Chi Him Kendrick Yiu
JCJack Cheeseman
Jack Cheeseman
GEGeorgia Elgood-Hunt
Georgia Elgood-Hunt
CMChenhan Sam Ma
Chenhan Sam Ma
ABAbhirup Banerjee
Abhirup Banerjee
SRSvetlana Reilly
Svetlana Reilly
Background: Atrial adverse remodeling drives the maintenance and progression of atrial fibrillation (AF) through electrical and structural myocardial changes, often accompanied by inflammation. Circulating N-glycans are emerging as biomarkers in inflammatory diseases, yet their role in AF remains undefined. Methods: We profiled the serum N-glycome of 138 patients with AF, non-AF arrhythmias, or sinus rhythm (SR) controls from peripheral venous (PV) and coronary sinus (CS) samples using hydrophilic interaction liquid chromatography coupled with high-resolution mass spectrometry. Glycan traits associated with AF were identified via logistic regression adjusted for clinical risk factors. Multivariate glycan scores were derived from PV and CS datasets using LASSO regression. In a subset (N=37), plasma proteome profiling was performed with the Olink Reveal panel. Results: Sixty-two glycan peaks were detected; 27 in PV and 8 in CS serum differed significantly between AF and controls. PV and CS glycan scores accurately classified AF, with the PV score correlating with 11 plasma proteins linked to structural remodeling and thrombo-inflammatory processes. The most abundant glycan, A2G2S2 (peak 30), was associated with higher odds of AF after adjusting for confounders (OR 2.22 [95% CI: 1.40–3.75], P = 0.001). CS A2G2S2 correlated with C-reactive protein (R = 0.432, P = 0.0275) and was elevated in patients with left atrial enlargement (P = 0.0354), but unchanged in those with impaired left ventricular ejection fraction or hypertrophy. Conclusion: Integrated profiling of peripheral and cardiac serum identifies novel N-glycosylation signatures in AF. Specific cardiac and circulating N-glycan signatures, including A2G2S2, are associated with AF and reflect inflammation-driven atrial remodeling, highlighting potential mechanistic pathways and biomarker applications.